Biyolojik ajan kullanan çocuklarda tüberküloz sıklığının değerlendirilmesi

Amaç: Anti-TNF ilaçlar tüberküloz enfeksiyon riskini arttırırlar. Bu çalışmayla Anti-TNF ilaç kullanan hastalarda, tüberküloz gelişme sıklığını araştırmayı amaçladık. Gereç ve yöntem: Çalışmaya anti-TNF ilaç kullanan 115 çocuk hasta dahil edildi. Olguların klinik ve epidemiyolojik özellikleri retrospektif olarak değerlendirildi. Bulgular: Anti-TNF ilaç kullanan 115 olgu çalışmaya dahil edildi. Olguların tanıları; Juvenil Romatoid Artrit 76 (%66), Ülseratif Kolit 11 (%9,6), Crohn's 7 (%6), Ankilozan Spondilit 6 (%5,2), FMF 5 (%4,3), Psoriasis 4 (%3,5) şeklindeydi. Hastaların kullandığı ajanların dağılımı ise; etanersept 74 (%64,3), infliximab 17 (%14,8), adalimumab 17 (%14,8), anakinra 5 (%4,3) ve kanakinumab 2 (%1,7) şeklindeydi. Tüm vakaların iki aylıkken BCG aşısı olduğu öğrenildi, aşı kartları ve sağlık bakanlığının aşı takip sisteminden teyit edildi. Tüm olgulara TDT yapıldı ve TDT yanıtı <5mm 89 (%77,4), 5-9 mm 11 (%8,7), 10-14 mm 8 (%7,4), >15 mm 7 (%5,6) olarak ölçüldü. Latent tüberküloz tanısı alan 17 olguya 9 ay izoniazid (INH) profilaksisi başlandı. Olguların hiçbirinde aktif tüberküloz saptanmadı.Sonuç: Anti-TNF alan tüm hastaların tüberküloz açısından değerlendirilmesi gerekmektedir. Tedavi başlangıcında saptanmasa da tedavi süresince güncel kılavuzlar ışığında temas öyküsü, semptomlar, fizik muayene, akciğer grafisi ve TDT/IGRA ile düzenli tüberküloz taramasına devam edilmelidir.

Abstract

Purpose: Anti-TNF drugs increase the risk of tuberculosis. In this study we aimed to investigate the incidence of tuberculosis in patients using anti-TNF drugs.Methods: One hundred and fifteen pediatric cases which were received anti-TNF drugs were included in the study. The clinical and epidemiological characteristics of the cases were analyzed retrospectively.Results: One hundred and fifteen cases using anti-TNF drugs were included in the study. The diagnoses of the cases were as follows; Juvenile Rheumatoid Arthritis 76 (66%), Ulcerative Colitis 11 (9.6%), Crohn's 7 (6%), Ankylosing Spondylitis 6 (5.2%), FMF 5 (4.3%), Psoriasis 4 (%3.5). The distribution of the agents used by the patients was; etanercept 74 (64.3%), infliximab 17 (14.8%), adalimumab 17 (14.8%), anakinra 5 (4.3%), and canakinumab 2 (%1.7). It was learned that all cases had BCG vaccinations when they were two months old, confirmed by the vaccination cards and the ministry of health's vaccination follow-up system. TST was performed in all of the cases and TST response was measured as <5mm in 89 (77.4%), 5-9 mm in 11 (8.7%), 10-14 mm in 8 (7.4%), >15 mm in 7 (5.6%) cases. Isoniazid (INH) prophylaxis was started for nine months in 17 cases with the diagnosis of latent tuberculosis. Active tuberculosis was not detected in any of the cases.Conclusion: All patients receiving anti-TNF need to be evaluated for tuberculosis. Although it is not detected at the beginning of the treatment, regular tuberculosis screening should be continued during the treatment with contact history, symptoms, physical examination, chest X-ray, and TST/IGRA in light of current guidelines.

Anahtar kelimeler

tüberküloz çocuk anti-TNF tubercolosis pediatric

🔖

Bu Makaleye Atıf Yap

KARA, Y., KIZIL, M. C., NEPESOV, M. İ., TUFAN, A. K., CETIN, N., AYDEMİR, Y., BARIŞ, Z., ERDOĞAN, H. K., KILIÇ, Ö., DİNLEYİCİ, E. Ç. (2023). Biyolojik ajan kullanan çocuklarda tüberküloz sıklığının değerlendirilmesi. Pamukkale Tıp Dergisi, Cilt: 16 - Sayı: 2, 238–246. https://ajindex.com/articles/888214

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008 Feb;117(2):244-79
Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. AnnuRev Pathol. 2012; 7:353-84
Raychaudhuri S. P., Nguyen C. T., Raychaudhuri S. K., Gershwin M. E. Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun Rev. 2009;9(2):67-81
Wallis R. S., Broder M. S., Wong J. Y., Hanson M. E., Beenhouwer D. O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261-1265
Wallis RS. J Investig Dermatol Symp Proc. 2007 May; 12(1):16-21 doi: 10.1038/sj.jjdsymp.5650031 5. Taylor PC. Tumor necrosis factor-blocking therapies. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 5th ed. Philadelphia, PA: Mosby, Elsevier; 2015:492–510
Caso F, Costa L, Del Puente A, et al. Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies. Ther Adv Chronic Dis 2015; 6:328–38
Ungprasert P, Thongprayoon C, Davis JM, et al. 3rd. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: a meta-analysis. Semin Arthritis Rheum 2016; 45:428–38
Steigerwald KA, Ilowite NT. Novel treatment options for juvenile idiopathic arthritis. Expert Rev Clin Pharmacol 2015; 8:559–73. 4
Turkish Ministry of Health, Public Health Institution of Turkey, Tuberculosis Guide for Patients Using Anti-TNF, Ankara, 2016
British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60(10):800-805
Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49(RR-6):1-51
Borekci, S., Atahan, E., Demir Yilmaz, D., Mazıcan, N., Duman, B., Ozguler, Y. et al. (2015). Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment. Respiration; international review of thoracic diseases, 2015;90(3), 191–198